Clinical trial NCT01713257: Study of Arginine Free IED in Critically Ill Patients.
Official title: A Comparative Randomized Controlled Study of Arginine Free Immunoenhancing Diet and Isocaloric, Isonitrogenous Formula in Critically Ill Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Critical Illness
Keywords: Critically ill patients
Lead sponsor: Thai Otsuka Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2012-10-24
Enrollment: 172
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study intends to investigate the clinical outcomes of a new immunoenhancing formula which composed arginine free compare to isonitrogenous, isocaloric standard formula in ICU patients.The study design is multicenter, double-blind randomized controlled study with 3 periods of Screening, Run-in and Randomization period.

Primary Objective: To evaluate the clinical outcomes of immunoenhancing diet (IED) arginine free in medical-surgical ICU patients.

Secondary Objective: To evaluate the immunologic effects and safety of IED arginine free formula.

Detailed description: It is accepted that nutrition support is essential in the treatment of critically ill patients. It is also reasonable to initiate nutrition support therapy as soon as possible. Although malnutrition is most frequently associated with a risk for immune dysfunction, it can affect all organ systems. Thus, ICU patients are in need of immunonutrients supplementation. An additional strategy to maximize the benefits is to consider using products supplemented with specific nutrients that modulate the immune system, improve wound healing, and reduce oxidative stress. The lower incidence of infectious complications may follow in shorter lengths of both intensive care units (ICU) and hospital stays. Many studies have concentrated on nutrients to stimulate the function of cellular immunity in these patients. These nutrients include arginine, glutamine and omega-3 fatty acid which has direct effect on T lymphocytes and macrophage. Enteral formulas designed as immune-enhancing diets (IED) contain supplemental amounts of L-arginine, L-glutamine, nucleotides and the long chain polyunsaturated fatty acids: eicosapentaenoic acid (EPA), docosahexanoic acid (DHA) and arachidonic acid (ARA) in addition to nutrient substrates essential for general nutrition and metabolism. These formulas vary considerably in composition of these four primary substrates. They introduce the immune cell function augmentation, inflammation regulation and infections minimization. Glutamine, a conditional-essential amino acid, an essential energy source, a precursor for protein synthesis and donates nitrogen for the synthesis of purines, pyrimidines, nucleotides, amino sugars, and glutathione antioxidant.

Glutamine also plays an important role in enhancing immune cell function with no elevation in proinflammatory cytokine production. The lower levels of glutamine have been associated with impaired tissue healing, immune dysfunction and increased mortality.

Omega-3 fatty acid (n-3 fatty acid or omega-3 fatty acid) directly affects the function of monocyte by membrane characteristic alteration, prostaglandin E2 (PGE2) synthesis that has the action of macrophage phagocytosis, IL-1 and superoxide synthesis. Moreover, omega-3 fatty acid reduces cellular immune response reaction by compete arachidonic acid resulting in less inflammation.

Arginine is considered a nutrient that enhances the immune response. Studies have shown arginine-supplemented immune formulas in helping decrease protein catabolism, improve nitrogen balance, enhance wound healing and wound strength resulted in less infection and shorter hospitalization days. Arginine has also been shown to support the immune system by enhancing lymphocyte proliferation and phagocytosis. Arginine may provide some benefits. However, recent meta-analysis conducted in a subgroup of critically ill patients by Heyland and colleagues revealed that arginine may be harmful to some group especially septic patients by stimulating nitric oxide (NO) production.

Based on these scientific rationales, it is recommended that arginine should not be used in critically ill patients who are clearly septic. And many evidences exist for supplementation with antioxidant and immunonutrition in the critically ill. Glutamine and fish oil/borage oil should be considered. These result in the development of immune-enhancing diet (IED) without arginine. In addition, two types of lipids are added into the formula to further modulate immune response. First, fish oil as a source of omega-3 fatty acids and borage oil as a source of docosahexanoic acid (DHA), a unique omega-6 fatty acid (n-6 fatty acid). Both n-3 and n-6 fatty acids are polyunsaturated fatty acids (PUFAs) and are essential fatty acids (EFA). Therefore, immune-enhancing diet composes of L-glutamine, eicosapentaenoic acid (EPA), docosahexanoic acid (DHA), antioxidant vitamins and trace minerals such as vitamin A, vitamin E, vitamin C, selenium and betacarotene.

Eligibility criteria: Inclusion Criteria:

1. ICU patients requiring mechanical ventilation or APACHE II score equal or more than 10
2. Patients arrived at ICU within 24 hours before feeding
3. Anticipated tube feeding for at least 5 days
4. Age of 18 years and older

Exclusion Criteria:

1. Inability to be fed via the gastrointestinal tract
2. Allergic to whey protein isolate (WPI), soy protein isolate, glutamine, fish oil or any components in study formulas
3. Hemodynamically unstable, requiring significant dose of vasopressor or inotropes infusion (Dopamine or dobutamine \> 5 microgram/kg/min or noradrenaline \> 0.1 microgram/kg/min)
4. Known insulin dependent diabetes mellitus
5. Cerebral hemorrhage or severe head injury (Glasgow Coma Scale Score ≤ 8)
6. Active bleeding requiring ongoing blood transfusion
7. Platelet count \< 30,000/mm3 or INR \> 5
8. Pre-existing incurable disease (uncontrolled cancer, terminal disease, patient's legal representative not committed to full support)
9. On chemotherapy, radiation therapy within the previous 6 months or immunosuppressive regimen (including prednisolone or aspirin at least 7 days consecutively within the previous 4 weeks) or on other investigational drugs
10. Any genetic immune or autoimmune disorder; known HIV-positive patients
11. Severe chronic liver disease (Child- Pugh score of 11-15)
12. Renal failure requiring renal replacement therapy
13. Pregnancy or lactation
14. Unable to obtain inform consent from patient or his/her legal representative

Primary outcomes:
measure: Development of new organ failure
timeFrame: 10 days
Secondary outcomes:
measure: Immunologic parameters
timeFrame: 10 days
Other outcomes:
Locations:
city: Muang
country: Thailand
facility: Assoc.Prof.Kaweesak Chittawatanarat
state: Chiang Mai
city: Muang
country: Thailand
facility: Assoc.Prof.Boonsong Pachanasoonthorn
state: Khonkaen
city: Haad Yai
country: Thailand
facility: Songklanakarind Hospital
state: Songkla
Study officials:
affiliation: Faculty of Medicine, Khon Kaen University
name: Assist.Prof.Boonsong Pajanasoontorn, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Faculty of Medicine, Chiang Mai University
name: Kaweesak Chittawatanarat, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Surgery, Faculty of Medicine, Songklanagarind University
name: Burapat Sangthong, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Medicine, Faculty of Medicine, Songklanakarind University
name: Rungsun Bhurayanontachai, M.D.
role: PRINCIPAL_INVESTIGATOR
References: